The estimated Net Worth of Linda M Richardson is at least $1.25 Milion dollars as of 1 December 2017. Ms Richardson owns over 19,833 units of Intercept Pharmaceuticals Inc stock worth over $1,158,924 and over the last 11 years she sold ICPT stock worth over $88,654.
Ms has made over 1 trades of the Intercept Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 19,833 units of ICPT stock worth $88,654 on 1 December 2017.
The largest trade she's ever made was selling 19,833 units of Intercept Pharmaceuticals Inc stock on 1 December 2017 worth over $88,654. On average, Ms trades about 735 units every 0 days since 2014. As of 1 December 2017 she still owns at least 60,996 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Ms Richardson stock trades at the bottom of the page.
Linda M. Richardson is the Exec. VP & Chief Commercial Officer at Intercept Pharmaceuticals Inc.
Ms Richardson is 57, she's been the Exec. VP & Chief Commercial Officer of Intercept Pharmaceuticals Inc since . There are 7 older and 17 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Linda's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 305 MADISON AVENUE, MORRISTOWN, NJ, 07960.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein a Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: